MRNA vs. ROIV: Moderna vs. Roivant Sciences Stock Comparison

November 11, 2026

How do Moderna (MRNA) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Moderna (MRNA) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Moderna (MRNA) and Roivant Sciences (ROIV)
Profile Item	MRNA	ROIV
Name	Moderna Inc.	Roivant Sciences Ltd.
Country/Region	United States	United Kingdom
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	101.48 billion USD	28.08 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	December 7, 2018	December 8, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MRNA

ROIV

GSPC

Moderna (MRNA) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Moderna (MRNA) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Moderna (MRNA) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
Total Return (1Y)	1,031.66%	96.75%
Total Return (3Y, Annualized)	58.68%	68.04%
Total Return (5Y, Annualized)	3.23%	36.73%

Risk Profile

Drawdown History

MRNA

ROIV

GSPC

Moderna (MRNA) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Moderna (MRNA) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
Volatility (1Y, Annualized)	194.88%	47.99%
Beta (5Y)	1.08	1.17
Max Drawdown (5Y)	-93.93%	-79.22%
Avg. Volume (3M)	21.61M	7.82M

Risk-Adjusted Performance

Risk-Return Positioning

MRNA and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
Sharpe Ratio (1Y)	5.27	1.93
Sortino Ratio (1Y)	20.44	4.03

Profitability

ROE (TTM)

Both Moderna (MRNA) at -39.00% and Roivant Sciences (ROIV) at -8.52% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
MRNA: -39.00%
Q1: -64.05%
Min: -167.77%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Roivant Sciences (ROIV) reports 0.00%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
MRNA: -141.43%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Moderna (MRNA) at -557.93% and Roivant Sciences (ROIV) at -25,408.11% report negative operating margin values, usually indicating operating losses over the period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
MRNA: -557.93%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
ROE (TTM)	-39.00%	-8.52%
ROA (TTM)	-13.26%	-16.28%
Net Margin (TTM)	-141.43%	0.00%
Operating Margin (TTM)	-557.93%	-25,408.11%
Gross Margin (TTM)	-66.02%	0.00%

Growth

Revenue Growth

Both Moderna (MRNA) at -39.92% and Roivant Sciences (ROIV) at -71.57% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Moderna (MRNA) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
Revenue Growth (YoY)	-39.92%	-71.57%
Revenue Growth (3Y CAGR)	-53.30%	-36.01%
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MRNA: 2.30
Min: 0.10

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Moderna (MRNA) at 0.19 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
MRNA: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
Current Ratio (MRQ)	2.30	16.72
Debt / Equity (MRQ)	0.19	0.02
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Moderna (MRNA) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Moderna (MRNA) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Moderna (MRNA) nor Roivant Sciences (ROIV) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
MRNA: --

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

Moderna (MRNA) vs. Roivant Sciences (ROIV): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Both look expensive on sales: Moderna (MRNA) at 45.55 sits in the upper P/S ratio quartile, and Roivant Sciences (ROIV) at 3,728.61 prices even higher, above its industry range.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max: 58.18
MRNA: 45.55
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Moderna (MRNA) at 11.58 and Roivant Sciences (ROIV) at 6.64 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max: 13.53
MRNA: 11.58
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Moderna (MRNA) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Moderna (MRNA) and Roivant Sciences (ROIV)
Metric	MRNA	ROIV
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	45.55	3,728.61
P/B Ratio (MRQ)	11.58	6.64
Free Cash Flow Yield (TTM)	0.29%	-3.98%